



## Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

DUBLIN, Jan. 3, 2024 /PRNewswire/ -- [Alkermes plc](#) (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on [www.alkermes.com](http://www.alkermes.com) and will be archived for 14 days.

### **About Alkermes plc**

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at [www.alkermes.com](http://www.alkermes.com).

Alkermes Contact:  
Jamie Constantine  
Investor Relations  
+1 781 873 2402



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302025512.html>

SOURCE Alkermes plc